30th Mar 2016 11:06
LONDON (Alliance News) - Drug development company Summit Therapeutics PLC on Wednesday said it has received positive interim data from ongoing phase one trials on a new formulation of its SMT C1100 compound in treating Duchenne muscular dystrophy.
All patients achieved plasma drug levels in the range believed to be necessary to deliver potential therapeutic benefits, Summit said.
The phase one trials are ongoing as Summit seeks to progress the drug to a phase two proof-of-concept clinical trial.
"These initial data are encouraging regarding the potential development of an improved formulation that could achieve blood levels of SMT C1100 that are above those observed with our current formulation," said Ralf Rosskamp, managing director and chief medical officer at Summit.
Summit shares were down 4.2% to 92.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L